Free Streaming News

David Johnson

Contact Info

FOLLOWERS (See All)

  • avatar
  • avatar
UPDATE: Compass Point Raises PT to $61.50 on Equity Residential on Valuation
05/30/2012 - 11:52am

Compass Points reiterates its Neutral rating on Equity Residential (NYSE: EQR) and raises its price target from $57.50 to $61.50.

Compass Points notes, "We are incrementally more positive on EQR's valuation, but still believe the stock is fairly valued at current levels.

UPDATE: Wunderlich Securities Cuts PT to $56 on DIRECTV on Brazil Macro Concerns
05/30/2012 - 11:52am

Wunderlich Securities reduces its price target on DIRECTV (NASDAQ: DTV) from $60 to $56, but reiterates its Buy rating on shares.

Wunderlich Securities comments, "We are lowering our price target on Buy-rated DirecTV (DTV) to $56 from $60 off the deteriorating Brazilian reais exchange rate and a lower 60,000 (vs.

UPDATE: Stifel Nicolaus Downgrades LeCroy Corporation to Hold Post Acquisition
05/30/2012 - 11:00am

Stifel Nicolaus reduces its rating on LeCroy Corporation (NASDAQ: LCRY) from Buy to Hold and suspends its PT to $14.

Stifel Nicolaus says, "On May 29th before the market open, LeCroy announced it entered into a definitive agreement to be acquired by Teledyne (TDY, Buy, $60.62, covered by our colleague Steve Levenson) for $14.30 a share in cash.

UPDATE: Stifel Nicolaus Reduces PT to $50 on Endo Pharmaceuticals Post Lidoderm Settlement
05/30/2012 - 11:00am

Stifel Nicolaus reiterates its Buy rating on Endo Pharmaceuticals (NASDAQ: ENDP) and reduces its price target from $53 to $50.

UPDATE: Citigroup Lowers PT to $9.50 on Research in Motion; Fundamentals Worse Than Expected
05/30/2012 - 10:36am

Citigroup reiterates its Sell/High Risk rating on Research in Motion (NASDAQ: RIMM) and reduces its price target from $11.75 to $9.50.

Citigroup notes, "We reiterate our Sell rating & reduce our target price to $9.50 from $11.75. We are now valuing this company on a price to tangible book value basis given the significantly lower earnings base.

UPDATE: Piper Jaffray Cuts PT to $19 on Finisar Corporation on Continued Weak Demand
05/30/2012 - 10:34am

Piper Jaffray reduces its price target from $22 to $19 on Finisar Corporation (NASDAQ: FNSR) but reiterates its Overweight rating on shares.

Piper Jaffray says, "We believe the 2H set up for Finisar is favorable, but headwinds from Europe will likely limit any stock appreciation over the next 1-2 quarters.

JP Morgan Raises PT to $570 on Intuitive Surgical Following Surgeon Feedback
05/30/2012 - 10:23am

JP Morgan reiterates its Neutral rating on Intuitive Surgical (NASDAQ: ISRG) and raises its price target from $500 to $570.

JP Morgan comments, "We recently surveyed general surgeons (n=28) to gauge interest in the use of da Vinci for new indications, beyond the early successful foothold in prostatectomy and hysterectomy.

UPDATE: Goldman Sachs Lowers PT to $13 on Research in Motion on Weaker Shipment Trajectory
05/30/2012 - 10:23am

Goldman Sachs reiterates its Neutral rating on Research in Motion (NASDAQ: RIMM) and reduces its price target from $14 to $13.

Goldman Sachs notes, "RIM's negative operating profit expectation is a disappointment even relative to our below-consensus estimates. We hadn't modeled negative operating margins until the Nov-14 quarter previously.

UPDATE: Morgan Stanley Raises PT to $43 on Madison Square Garden on Higher Affiliate Fees
05/30/2012 - 10:07am

Morgan Stanley reiterates its Overweight rating on Madison Square Garden (NASDAQ: MSG) and increases its price target from $36 to $43.

UPDATE: Wedbush Reduces PT to $9.50 on Research in Motion Post CEO Update
05/30/2012 - 10:06am

Wedbush reduces its price target on Research in Motion (NASDAQ: RIMM) from $11.50 to $9.50 as it reiterates a Neutral rating on shares.

Wedbush notes, "We continue to remain cautious on RIM and are reducing our estimates to reflect comments made by RIM's CEO in his business update.

The David Johnson content filter

Analyst Ratings(4354)
Price Target(3876)
Analyst Color(3687)
Reiteration(3050)
Pre-Market Outlook(2254)

Quick Stats

Articles Published4439
Total Article Page Views230548
Contributor Since12/2011
Enter your question
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
No questions/answers for the author.
See All

Latest from Premium

UPDATE: Compass Point Raises PT to $61.50 on Equity Residential on Valuation
05/30/2012 - 11:52am

Compass Points reiterates its Neutral rating on Equity Residential (NYSE: EQR) and raises its price target from $57.50 to $61.50.

Compass Points notes, "We are incrementally more positive on EQR's valuation, but still believe the stock is fairly valued at current levels.

UPDATE: Wunderlich Securities Cuts PT to $56 on DIRECTV on Brazil Macro Concerns
05/30/2012 - 11:52am

Wunderlich Securities reduces its price target on DIRECTV (NASDAQ: DTV) from $60 to $56, but reiterates its Buy rating on shares.

Wunderlich Securities comments, "We are lowering our price target on Buy-rated DirecTV (DTV) to $56 from $60 off the deteriorating Brazilian reais exchange rate and a lower 60,000 (vs.

UPDATE: Stifel Nicolaus Downgrades LeCroy Corporation to Hold Post Acquisition
05/30/2012 - 11:00am

Stifel Nicolaus reduces its rating on LeCroy Corporation (NASDAQ: LCRY) from Buy to Hold and suspends its PT to $14.

Stifel Nicolaus says, "On May 29th before the market open, LeCroy announced it entered into a definitive agreement to be acquired by Teledyne (TDY, Buy, $60.62, covered by our colleague Steve Levenson) for $14.30 a share in cash.

UPDATE: Stifel Nicolaus Reduces PT to $50 on Endo Pharmaceuticals Post Lidoderm Settlement
05/30/2012 - 11:00am

Stifel Nicolaus reiterates its Buy rating on Endo Pharmaceuticals (NASDAQ: ENDP) and reduces its price target from $53 to $50.

UPDATE: Citigroup Lowers PT to $9.50 on Research in Motion; Fundamentals Worse Than Expected
05/30/2012 - 10:36am

Citigroup reiterates its Sell/High Risk rating on Research in Motion (NASDAQ: RIMM) and reduces its price target from $11.75 to $9.50.

Citigroup notes, "We reiterate our Sell rating & reduce our target price to $9.50 from $11.75. We are now valuing this company on a price to tangible book value basis given the significantly lower earnings base.

UPDATE: Piper Jaffray Cuts PT to $19 on Finisar Corporation on Continued Weak Demand
05/30/2012 - 10:34am

Piper Jaffray reduces its price target from $22 to $19 on Finisar Corporation (NASDAQ: FNSR) but reiterates its Overweight rating on shares.

Piper Jaffray says, "We believe the 2H set up for Finisar is favorable, but headwinds from Europe will likely limit any stock appreciation over the next 1-2 quarters.

JP Morgan Raises PT to $570 on Intuitive Surgical Following Surgeon Feedback
05/30/2012 - 10:23am

JP Morgan reiterates its Neutral rating on Intuitive Surgical (NASDAQ: ISRG) and raises its price target from $500 to $570.

JP Morgan comments, "We recently surveyed general surgeons (n=28) to gauge interest in the use of da Vinci for new indications, beyond the early successful foothold in prostatectomy and hysterectomy.

UPDATE: Goldman Sachs Lowers PT to $13 on Research in Motion on Weaker Shipment Trajectory
05/30/2012 - 10:23am

Goldman Sachs reiterates its Neutral rating on Research in Motion (NASDAQ: RIMM) and reduces its price target from $14 to $13.

Goldman Sachs notes, "RIM's negative operating profit expectation is a disappointment even relative to our below-consensus estimates. We hadn't modeled negative operating margins until the Nov-14 quarter previously.

UPDATE: Morgan Stanley Raises PT to $43 on Madison Square Garden on Higher Affiliate Fees
05/30/2012 - 10:07am

Morgan Stanley reiterates its Overweight rating on Madison Square Garden (NASDAQ: MSG) and increases its price target from $36 to $43.

UPDATE: Wedbush Reduces PT to $9.50 on Research in Motion Post CEO Update
05/30/2012 - 10:06am

Wedbush reduces its price target on Research in Motion (NASDAQ: RIMM) from $11.50 to $9.50 as it reiterates a Neutral rating on shares.

Wedbush notes, "We continue to remain cautious on RIM and are reducing our estimates to reflect comments made by RIM's CEO in his business update.